title: Kainate-induced changes in opioid peptide genes and AP-1 protein expression in the rat hippocampus.
abstract: In the rat hippocampus, jun, c-fos, and fos-related antigen immunoreactivity, AP-1 DNA binding, and opioid peptide gene expression were examined after kainate treatment to determine whether the induction and DNA binding of AP-1 transcription factors are correlated with the expression of the opioid peptide genes. One and one-half hours after kainate administration, fos-related antigen and jun immunoreactivity and AP-1 DNA binding were induced; maximal elevation was observed after 4.5 h. Transcription factor expression and DNA binding increased in a dose-dependent manner. Preprodynorphin and preproenkephalin mRNA induction was also dose dependent. The anticonvulsants, pentobarbital and diazepam, effectively blocked electroencephalographic seizure activity caused by kainate treatment, whereas valproic acid was approximately 50% effective. Opioid peptide gene expression, fos-related antigen and jun immunoreactivity, and AP-1 DNA binding all reflected similar reductions after anticonvulsant treatment. Therefore, expression and DNA binding activity of the AP-1 transcription factors are correlated with opioid peptide gene expression in the rat hippocampus.
authors.affiliation: Laboratory of Molecular and Integrative Neuroscience, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709.
authors.forename: K R
authors.initials: KR
authors.lastname: Pennypacker
authors.forename: D
authors.initials: D
authors.lastname: Walczak
authors.forename: L
authors.initials: L
authors.lastname: Thai
authors.forename: R
authors.initials: R
authors.lastname: Fannin
authors.forename: E
authors.initials: E
authors.lastname: Mason
authors.forename: J
authors.initials: J
authors.lastname: Douglass
authors.forename: J S
authors.initials: JS
authors.lastname: Hong
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001483:Base Sequence; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004723:Endorphins / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects; D005796:Genes / Q000187:drug effects*; D006624:Hippocampus / Q000378:metabolism / Q000502:physiology*; D007608:Kainic Acid / Q000494:pharmacology*; D008297:Male; D015335:Molecular Probes / Q000235:genetics; D008969:Molecular Sequence Data; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology; D014157:Transcription Factors / Q000378:metabolism / Q000502:physiology
chemical_list: D000927:Anticonvulsants; D004723:Endorphins; D015335:Molecular Probes; D016755:Proto-Oncogene Proteins c-jun; D014157:Transcription Factors; D004247:DNA; D007608:Kainic Acid